• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION
【24h】

ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION

机译：他汀类药物在年龄相关性黄斑变性的发生和发展中的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To determine if statins are associated with the development or progression of age-related macular degeneration (AMD). Methods: A large, national insurance claims database was reviewed to identify individuals aged 60 years or older who were enrolled for >2 years and had >1 visits to an eye provider. Prescription claims for statins within a 24-month look-back period and outpatient lipid laboratory values were also reviewed. Cox regression analysis was used to determine whether statin use was associated with the development of nonexudative or exudative AMD or progressing from nonexudative to exudative AMD. Results: Of the 107,007 beneficiaries eligible for the nonexudative AMD analysis, 4,647 incident cases of nonexudative AMD occurred. Seven hundred and ninety-two incident cases of exudative AMD were found among the 113,111 beneficiaries eligible for the exudative AMD analysis. Of the 10,743 beneficiaries with known nonexudative AMD eligible for the progression model, 404 progressed to exudative AMD during their time in the plan. After multivariable analysis, statin use was not associated with the development of nonexudative AMD (P > 0.05). Statin use of >12 months was associated with an increased hazard for developing exudative AMD (P < 0.005). Among those taking statins, only enrollees with the highest lipid levels had an increased hazard of developing exudative AMD (P < 0.05). Conclusion: In those with elevated lipid levels, >1 year of statin use was associated with an increased hazard for exudative AMD. Lipid status influences the relationship between statins and the risk of AMD. Because of a number of limitations in study design, these observations warrant further study and should not be the rationale for any changes in the use of statins to treat dyslipidemias.
机译：目的：确定他汀类药物是否与年龄相关性黄斑变性（AMD）的发生或发展有关。方法：对大型的国家保险理赔数据库进行了审查，以识别年龄在60岁或以上且参加了> 2年且拜访眼科医生的患者> 1次的个人。还回顾了他汀类药物在24个月的回顾期内的处方要求和门诊脂质实验室的价值。使用Cox回归分析来确定他汀类药物的使用是否与非渗出性或渗出​​性AMD的发展有关，或从非渗出性变为渗出性AMD的进展。结果：在符合非渗出性AMD分析的107,007名受益人中，发生了4,647起非渗出性AMD事件。在113,111名符合渗出性AMD分析的受益人中，发现了792例渗出性AMD事件。在10,743名已知具有非渗出性AMD且符合进展模型的受益人中，有404人在计划期间已发展为渗出性AMD。经过多变量分析后，他汀类药物的使用与非渗出性AMD的发生无关（P> 0.05）。他汀类药物使用时间超过12个月与发生渗出性AMD的危险增加有关（P <0.005）。在服用他汀类药物的人群中，只有脂质水平最高的受试者出现渗出性AMD的危险增加（P <0.05）。结论：在血脂水平升高的人群中，使用他汀类药物> 1年与渗出性AMD的危险增加有关。脂质状态影响他汀类药物与AMD风险之间的关系。由于研究设计的诸多局限性，这些观察结果值得进一步研究，而不应成为使用他汀类药物治疗血脂异常的任何理由。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号